Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Prepaid Assets (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Prepaid Assets data on record, last reported at $31.6 million in Q3 2025.

  • For Q3 2025, Prepaid Assets changed N/A year-over-year to $31.6 million; the TTM value through Sep 2025 reached $31.6 million, changed N/A, while the annual FY2024 figure was $18.4 million, 113.76% up from the prior year.
  • Prepaid Assets reached $31.6 million in Q3 2025 per APLS's latest filing, up from $18.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $43.2 million in Q1 2024 and bottomed at $5.2 million in Q4 2021.
  • Average Prepaid Assets over 5 years is $22.7 million, with a median of $21.5 million recorded in 2022.
  • The widest YoY moves for Prepaid Assets: up 961.33% in 2021, down 80.77% in 2021.
  • A 5-year view of Prepaid Assets shows it stood at $5.2 million in 2021, then surged by 609.19% to $36.7 million in 2022, then tumbled by 76.56% to $8.6 million in 2023, then skyrocketed by 113.76% to $18.4 million in 2024, then skyrocketed by 71.82% to $31.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $31.6 million in Q3 2025, $18.4 million in Q4 2024, and $11.8 million in Q2 2024.